

**Clinical trial results:****A Randomized, Parallel, Double-blind, Placebo-controlled, Dose-ranging, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD8233 Treatment in Participants With Dyslipidemia****Summary**

| | |
|--------------------------|----------------|
| EudraCT number | 2020-000767-23 |
| Trial protocol | SK DK |
| Global end of trial date | 20 July 2021 |

Results information

| | |
|--------------------------------|---|
| Result version number | v2 (current) |
| This version publication date | 08 March 2023 |
| First version publication date | 03 August 2022 |
| Version creation reason | • Correction of full data set Aligning with CTGOV posting. |

Trial information**Trial identification**

| | |
|-----------------------|-------------|
| Sponsor protocol code | D7990C00003 |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | AstraZeneca |
| Sponsor organisation address | Astraalléen, Södertälje, Sweden, |
| Public contact | Information Center, AstraZeneca, information.center@astrazeneca.com |
| Scientific contact | Global Clinical Lead, AstraZeneca, +1 18772409479, information.center@astrazeneca.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 26 August 2021 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 20 July 2021 |
| Global end of trial reached? | Yes |
| Global end of trial date | 20 July 2021 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To investigate the effect of AZD8233 on level of dyslipidemia related biomarker (LDL-C) across different dose levels (absolute change from baseline in log transformed LDL-C in plasma).

Protection of trial subjects:

This study was performed in compliance with International Council for Harmonisation (ICH) Good Clinical Practice, including the archiving of essential documents.

Background therapy: -

Evidence for comparator: -

| | |
|---|-----------------|
| Actual start date of recruitment | 28 October 2020 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | United States: 50 |
| Country: Number of subjects enrolled | Denmark: 25 |
| Country: Number of subjects enrolled | Slovakia: 44 |
| Worldwide total number of subjects | 119 |
| EEA total number of subjects | 69 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 72 |
| From 65 to 84 years | 47 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

This study was conducted at 19 clinical research center in Denmark, Slovakia and the USA. First subject enrolled (First subject first visit/first consent signed date): 28 October 2020. Last subject last visit: 20 July 2021.

Pre-assignment

Screening details:

Following a screening period of up to 42 days, eligible participants received an SC injection of study intervention on Days 1, 8, 29, and 57.

Period 1

| | |
|------------------------------|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor, Data analyst, Carer, Assessor |

Arms

| | |
|------------------------------|------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | AZD8233 low dose |

Arm description:

AZD8233 low dose for subcutaneous injection.

| | |
|--|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | AZD8233 low dose |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Subcutaneous injection on Days 1, 8, 29, and 57

| | |
|------------------|---------------------|
| Arm title | AZD8233 medium dose |
|------------------|---------------------|

Arm description:

AZD8233 medium dose

| | |
|--|---------------------|
| Arm type | Experimental |
| Investigational medicinal product name | AZD8233 medium dose |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Subcutaneous injection on Days 1, 8, 29, and 57.

| | |
|------------------|-------------------|
| Arm title | AZD8233 high dose |
|------------------|-------------------|

Arm description:

AZD8233 high dose

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|-------------------|
| Investigational medicinal product name | AZD8233 high dose |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| Subcutaneous injection on Days 1, 8, 29, and 57. | |
| Arm title | Placebo |

Arm description:

Placebo

| | |
|--|------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Subcutaneous injection on Days 1, 8, 29, and 57

| Number of subjects in period 1 | AZD8233 low dose | AZD8233 medium dose | AZD8233 high dose |
|---------------------------------------|------------------|---------------------|-------------------|
| Started | 30 | 30 | 29 |
| Completed | 28 | 29 | 27 |
| Not completed | 2 | 1 | 2 |
| Consent withdrawn by subject | 1 | - | - |
| Reason not given | 1 | - | - |
| Adverse event, non-fatal | - | - | 2 |
| Lost to follow-up | - | 1 | - |

| Number of subjects in period 1 | Placebo |
|---------------------------------------|---------|
| Started | 30 |
| Completed | 30 |
| Not completed | 0 |
| Consent withdrawn by subject | - |
| Reason not given | - |
| Adverse event, non-fatal | - |
| Lost to follow-up | - |

Baseline characteristics

Reporting groups

| | |
|--|---------------------|
| Reporting group title | AZD8233 low dose |
| Reporting group description: AZD8233 low dose for subcutaneous injection. | |
| Reporting group title | AZD8233 medium dose |
| Reporting group description: AZD8233 medium dose | |
| Reporting group title | AZD8233 high dose |
| Reporting group description: AZD8233 high dose | |
| Reporting group title | Placebo |
| Reporting group description: Placebo | |

| Reporting group values | AZD8233 low dose | AZD8233 medium dose | AZD8233 high dose |
|--|------------------|---------------------|-------------------|
| Number of subjects | 30 | 30 | 29 |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 18 | 20 | 18 |
| From 65-84 years | 12 | 10 | 11 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous Units: Years | | | |
| arithmetic mean | 61.8 | 60.6 | 60.4 |
| standard deviation | ± 7.1 | ± 7.4 | ± 8.4 |
| Sex: Female, Male Units: Participants | | | |
| Female | 16 | 12 | 11 |
| Male | 14 | 18 | 18 |
| Race (NIH/OMB) Units: Subjects | | | |
| AMERICAN INDIAN OR ALASKA NATIVE | 0 | 0 | 0 |
| ASIAN | 1 | 0 | 0 |
| BLACK OR AFRICAN AMERICAN | 2 | 2 | 1 |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 | 0 | 0 |
| WHITE | 27 | 28 | 28 |

| | | | |
|------------------------|---------|-------|--|
| Reporting group values | Placebo | Total | |
|------------------------|---------|-------|--|

| | | | |
|---|-------|-----|--|
| Number of subjects | 30 | 119 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 16 | 72 | |
| From 65-84 years | 14 | 47 | |
| 85 years and over | 0 | 0 | |
| Age Continuous | | | |
| Units: Years | | | |
| arithmetic mean | 63.9 | | |
| standard deviation | ± 7.3 | - | |
| Sex: Female, Male | | | |
| Units: Participants | | | |
| Female | 18 | 57 | |
| Male | 12 | 62 | |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| AMERICAN INDIAN OR ALASKA NATIVE | 0 | 0 | |
| ASIAN | 0 | 1 | |
| BLACK OR AFRICAN AMERICAN | 3 | 8 | |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 | 0 | |
| WHITE | 27 | 110 | |

End points

End points reporting groups

| | |
|--|---------------------|
| Reporting group title | AZD8233 low dose |
| Reporting group description: AZD8233 low dose for subcutaneous injection. | |
| Reporting group title | AZD8233 medium dose |
| Reporting group description: AZD8233 medium dose | |
| Reporting group title | AZD8233 high dose |
| Reporting group description: AZD8233 high dose | |
| Reporting group title | Placebo |
| Reporting group description: Placebo | |

Primary: Change in LDL-C at week 12.

| | |
|---|--|
| End point title | Change in LDL-C at week 12. ^[1] |
| End point description: | |
| End point type | Primary |
| End point timeframe: Baseline to week 12 | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No plasma concentrations were measured in placebo arm.

| End point values | AZD8233 low dose | AZD8233 medium dose | AZD8233 high dose | Placebo |
|--|------------------------|------------------------|------------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 30 | 30 | 29 | 30 |
| Units: Ratio | | | | |
| geometric mean (confidence interval 95%) | 0.606 (0.517 to 0.710) | 0.270 (0.230 to 0.317) | 0.206 (0.174 to 0.242) | 0.978 (0.834 to 1.147) |

Statistical analyses

No statistical analyses for this end point

Secondary: Relative change from baseline in PCSK9 concentration in plasma at week 12.

| | |
|------------------------|--|
| End point title | Relative change from baseline in PCSK9 concentration in plasma at week 12. |
| End point description: | |
| End point type | Secondary |

End point timeframe:

Baseline to week 12

| End point values | AZD8233 low dose | AZD8233 medium dose | AZD8233 high dose | Placebo |
|--|------------------------|------------------------|------------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 30 | 30 | 29 | 30 |
| Units: Ratio | | | | |
| geometric mean (confidence interval 95%) | 0.420 (0.340 to 0.520) | 0.110 (0.090 to 0.140) | 0.060 (0.050 to 0.080) | 0.950 (0.770 to 1.180) |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage change from baseline in concentration of TC, HDL-C, Non-HDL-C, VLDL-C, ApoA1, ApoB, Lp(a), Triglycerides, Remnants cholesterol

| | |
|-----------------|---|
| End point title | Percentage change from baseline in concentration of TC, HDL-C, Non-HDL-C, VLDL-C, ApoA1, ApoB, Lp(a), Triglycerides, Remnants cholesterol |
|-----------------|---|

End point description:

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline to week 12 | |

| End point values | AZD8233 low dose | AZD8233 medium dose | AZD8233 high dose | Placebo |
|--|---------------------------|---------------------------|---------------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 30 | 30 | 29 | 30 |
| Units: Percent | | | | |
| least squares mean (confidence interval 95%) | | | | |
| Triglycerides | -7.70 (-18.44 to 3.05) | -12.95 (-23.77 to -2.12) | -12.70 (-23.88 to -1.52) | 2.69 (-8.19 to 13.56) |
| Total cholesterol | -21.13 (-26.56 to -15.70) | -43.90 (-49.43 to -38.37) | -47.58 (-53.37 to -41.78) | -1.11 (-6.56 to 4.35) |
| HDL-C | 3.37 (-1.12 to 7.86) | 6.50 (1.96 to 11.04) | 5.57 (0.90 to 10.25) | 1.34 (-3.28 to 5.97) |
| Non-HDL-C | -29.57 (-36.58 to -22.56) | -61.25 (-68.38 to -54.11) | -67.92 (-75.38 to -60.45) | -0.65 (-7.81 to 6.51) |
| VLDL-C | -7.54 (-18.36 to 3.27) | -12.09 (-23.04 to -1.15) | -11.13 (-22.59 to 0.33) | 3.22 (-7.90 to 14.35) |
| ApoB | -29.50 (-35.64 to -23.35) | -60.13 (-66.33 to -53.93) | -67.07 (-73.46 to -60.68) | -1.65 (-7.83 to 4.53) |
| Remnants cholesterol | -13.50 (-39.57 to 12.56) | -16.54 (-42.97 to 9.88) | -26.84 (-54.23 to 0.54) | 6.38 (-20.28 to 33.05) |

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma concentration of AZD8233

| | |
|-----------------|--|
| End point title | Plasma concentration of AZD8233 ^[2] |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Measurement at week 1, week 4, week 6, week 8, week 10, week 12, week 16, week 20, week 24 after first dose administration.

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The primary analysis is presented in this table.

| End point values | AZD8233 low dose | AZD8233 medium dose | AZD8233 high dose | |
|--------------------------------------|------------------|---------------------|-------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 30 | 30 | 29 | |
| Units: ug/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| Week 1 | 0.346 (± 0.59) | 0.681 (± 0.24) | 1.201 (± 0.49) | |
| Week 4 | 0.238 (± 0.21) | 0.699 (± 0.33) | 1.366 (± 0.71) | |
| Week 6 | 0.288 (± 0.21) | 0.870 (± 0.34) | 1.917 (± 1.09) | |
| Week 8 | 0.152 (± 0.10) | 0.628 (± 0.57) | 1.000 (± 0.68) | |
| Week 10 | 0.241 (± 0.15) | 0.751 (± 0.29) | 1.562 (± 0.84) | |
| Week 12 | 0.134 (± 0.07) | 0.476 (± 0.23) | 0.976 (± 0.75) | |
| Week 16 | 0.087 (± 0.09) | 0.297 (± 0.53) | 0.507 (± 0.70) | |
| Week 20 | 0.053 (± 0.004) | 0.153 (± 0.26) | 0.376 (± 0.68) | |
| Week 24 | 0.111 (± 0.31) | 0.111 (± 0.15) | 0.350 (± 0.62) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-drug antibodies (ADAs) during the treatment period and follow-up period

| | |
|-----------------|--|
| End point title | Anti-drug antibodies (ADAs) during the treatment period and follow-up period |
|-----------------|--|

End point description:

ADA titre results for subjects with positive ADA.

| | |
|---|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Measurement at week 0, week 1, week 4, week 8, week 12, week 16, week 20, week 24 | |

| End point values | AZD8233 low dose | AZD8233 medium dose | AZD8233 high dose | Placebo |
|-------------------------------|-------------------|---------------------|-------------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 30 | 30 | 29 | 30 |
| Units: ADA titre | | | | |
| median (full range (min-max)) | | | | |
| Baseline | 100 (100 to 100) | 200 (200 to 200) | 0 (0 to 0) | 100 (100 to 100) |
| Week 1 | 100 (50 to 800) | 200 (200 to 200) | 0 (0 to 0) | 100 (100 to 100) |
| Week 4 | 150 (100 to 1600) | 200 (100 to 400) | 75 (50 to 100) | 100 (100 to 100) |
| Week 8 | 400 (200 to 3200) | 200 (100 to 400) | 75 (50 to 100) | 100 (100 to 100) |
| Week 12 | 200 (200 to 1600) | 200 (100 to 400) | 200 (200 to 200) | 50 (50 to 50) |
| Week 16 | 400 (100 to 1600) | 200 (50 to 400) | 300 (200 to 400) | 100 (100 to 100) |
| Week 20 | 400 (200 to 1600) | 200 (100 to 400) | 500 (200 to 800) | 100 (100 to 100) |
| Week 24 | 400 (200 to 800) | 300 (100 to 400) | 200 (50 to 800) | 100 (100 to 100) |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage change from baseline in levels of LDL-C in plasma

| | |
|------------------------|--|
| End point title | Percentage change from baseline in levels of LDL-C in plasma |
| End point description: | |

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline to week 12 | |

| End point values | AZD8233 low dose | AZD8233 medium dose | AZD8233 high dose | Placebo |
|--|---------------------------|---------------------------|---------------------------|-----------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 30 | 30 | 29 | 30 |
| Units: Percent | | | | |
| least squares mean (confidence interval 95%) | -32.22 (-39.79 to -24.66) | -69.26 (-76.89 to -61.63) | -76.50 (-84.37 to -68.63) | -1.53 (-9.14 to 6.09) |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage change from baseline to week 12 in Lp(a)

| | |
|-----------------|---|
| End point title | Percentage change from baseline to week 12 in Lp(a) |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline to week 12

| End point values | AZD8233 low dose | AZD8233 medium dose | AZD8233 high dose | Placebo |
|-------------------------------|-----------------------|-----------------------|-----------------------|---------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 26 | 28 | 26 | 24 |
| Units: Percent | | | | |
| median (full range (min-max)) | -6.94 (-68.0 to 15.2) | -38.89 (-88.2 to 0.0) | -44.66 (-84.1 to 0.0) | 0.0 (-43.3 to 50.7) |

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of subjects with an ECG determined to be abnormal and clinically significant

| | |
|-----------------|---|
| End point title | Number of subjects with an ECG determined to be abnormal and clinically significant |
|-----------------|---|

End point description:

| | |
|----------------|---------------------|
| End point type | Other pre-specified |
|----------------|---------------------|

End point timeframe:

Baseline to end of treatment

| End point values | AZD8233 low dose | AZD8233 medium dose | AZD8233 high dose | Placebo |
|-----------------------------|------------------|---------------------|-------------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 30 | 30 | 29 | 30 |
| Units: Number of subjects | | | | |
| Baseline | 0 | 0 | 0 | 0 |
| End of treatment | 0 | 0 | 0 | 0 |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug until last study visit

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|----|
| Dictionary version | 24 |
|--------------------|----|

Reporting groups

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description: -

| | |
|-----------------------|-----------------|
| Reporting group title | AZD8233 (50 mg) |
|-----------------------|-----------------|

Reporting group description: -

| | |
|-----------------------|-----------------|
| Reporting group title | AZD8233 (15 mg) |
|-----------------------|-----------------|

Reporting group description: -

| | |
|-----------------------|-----------------|
| Reporting group title | AZD8233 (90 mg) |
|-----------------------|-----------------|

Reporting group description: -

| Serious adverse events | Placebo | AZD8233 (50 mg) | AZD8233 (15 mg) |
|---|----------------|-----------------|-----------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 2 / 30 (6.67%) | 1 / 30 (3.33%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |
| Concussion | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|----------------|----------------|
| Cardiac failure acute | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Staphylococcal infection | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| COVID-19 pneumonia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|--|--|
| Serious adverse events | AZD8233 (90 mg) | | |
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |
| Injury, poisoning and procedural complications | | | |
| Concussion | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular disorders | | | |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac disorders | | | |

| | | | |
|---|----------------|--|--|
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac failure acute | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Staphylococcal infection | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| COVID-19 pneumonia | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Placebo | AZD8233 (50 mg) | AZD8233 (15 mg) |
|---|------------------|------------------|------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 12 / 30 (40.00%) | 17 / 30 (56.67%) | 14 / 30 (46.67%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Benign neoplasm of thyroid gland | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Seborrhoeic keratosis | | | |

| | | | |
|---|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 | 0 / 30 (0.00%) 0 |
| Vascular disorders | | | |
| Haematoma | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertension | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 1 | 1 |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 0 | 2 |
| Injection site haematoma | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 0 | 2 |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 4 | 1 |
| Injection site pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 2 / 30 (6.67%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 2 | 1 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| Benign prostatic hyperplasia subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Ovarian mass subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 |
| Pelvic pain subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 |
| Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 |
| Dyspnoea subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 |
| Oropharyngeal pain subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Psychiatric disorders | | | |
| Restlessness subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 |
| Investigations | | | |
| Alanine aminotransferase increased subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Blood creatine phosphokinase increased subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 |
| C-reactive protein increased | | | |

| | | | |
|--|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipids increased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urine albumin/creatinine ratio increased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Protein urine present | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Injury, poisoning and procedural complications | | | |
| Facial bones fracture | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Head injury | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Joint injury | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Radius fracture | | | |

| | | | |
|------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Post-traumatic neck syndrome | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin laceration | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth fracture | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Wrist fracture | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 1 | 0 | 1 |
| Palpitations | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Headache | | | |

| | | | |
|--------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 30 (0.00%) | 2 / 30 (6.67%) |
| occurrences (all) | 2 | 0 | 2 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Migraine | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 2 / 30 (6.67%) | 0 / 30 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Radiculopathy | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood and lymphatic system disorders | | | |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anaemia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 1 | 0 | 1 |
| Spontaneous haematoma | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 0 | 2 |
| Ear and labyrinth disorders | | | |
| Vertigo | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear disorder | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrointestinal disorders | | | |

| | | | |
|---|---------------------|---------------------|---------------------|
| Abdominal pain subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Abdominal pain upper subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Diarrhoea subjects affected / exposed occurrences (all) | 2 / 30 (6.67%) 3 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Toothache subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 |
| Nausea subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 | 0 / 30 (0.00%) 0 |
| Haemorrhoids subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 | 0 / 30 (0.00%) 0 |
| Skin and subcutaneous tissue disorders Erythema subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Pruritus subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Renal and urinary disorders Pollakiuria subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 2 / 30 (6.67%) 2 | 0 / 30 (0.00%) 0 |
| Back pain subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 1 / 30 (3.33%) 1 | 0 / 30 (0.00%) 0 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Cervical spinal stenosis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Spinal pain | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sacroiliitis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Wrist deformity | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 30 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 30 (3.33%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nasal vestibulitis | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 | 0 / 30 (0.00%) 0 |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 |
| Osteomyelitis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 | 0 / 30 (0.00%) 0 |
| Sinusitis subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Tooth infection subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Upper respiratory tract infection subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Urinary tract infection subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 30 (0.00%) 0 | 2 / 30 (6.67%) 2 |
| COVID-19 subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 30 (0.00%) 0 | 1 / 30 (3.33%) 1 |
| Asymptomatic COVID-19 subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Metabolism and nutrition disorders Hypokalaemia subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Hypoglycaemia subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 30 (0.00%) 0 | 0 / 30 (0.00%) 0 |

| | | | |
|---|-----------------|--|--|
| Non-serious adverse events | AZD8233 (90 mg) | | |
| Total subjects affected by non-serious adverse events | | | |

| | | | |
|---|------------------|--|--|
| subjects affected / exposed | 20 / 29 (68.97%) | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Benign neoplasm of thyroid gland | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Seborrhoeic keratosis | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vascular disorders | | | |
| Haematoma | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Hypertension | | | |
| subjects affected / exposed | 3 / 29 (10.34%) | | |
| occurrences (all) | 4 | | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Fatigue | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site haematoma | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site pain | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 2 / 29 (6.90%) | | |
| occurrences (all) | 2 | | |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Reproductive system and breast disorders | | | |
| Benign prostatic hyperplasia | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Ovarian mass | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Psychiatric disorders | | | |
| Restlessness | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Investigations | | | |
| Alanine aminotransferase increased | | | |

| | | | |
|--|----------------|--|--|
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| C-reactive protein increased | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Liver function test increased | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Lipids increased | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Transaminases increased | | | |
| subjects affected / exposed | 2 / 29 (6.90%) | | |
| occurrences (all) | 2 | | |
| Urine albumin/creatinine ratio increased | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Protein urine present | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injury, poisoning and procedural complications | | | |
| Facial bones fracture | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Fall | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Head injury | | | |

| | | | |
|------------------------------|----------------|--|--|
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Joint injury | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Radius fracture | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Post-traumatic neck syndrome | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Skin laceration | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 2 | | |
| Skin abrasion | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Tooth fracture | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Wrist fracture | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Palpitations | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|--------------------------------------|-----------------------------|----------------|--|
| Nervous system disorders | Dizziness | | |
| | subjects affected / exposed | 0 / 29 (0.00%) | |
| | occurrences (all) | 0 | |
| | Headache | | |
| | subjects affected / exposed | 1 / 29 (3.45%) | |
| | occurrences (all) | 1 | |
| | Hypoaesthesia | | |
| | subjects affected / exposed | 0 / 29 (0.00%) | |
| | occurrences (all) | 0 | |
| | Migraine | | |
| | subjects affected / exposed | 0 / 29 (0.00%) | |
| | occurrences (all) | 0 | |
| | Paraesthesia | | |
| | subjects affected / exposed | 0 / 29 (0.00%) | |
| | occurrences (all) | 0 | |
| | Radiculopathy | | |
| | subjects affected / exposed | 1 / 29 (3.45%) | |
| | occurrences (all) | 1 | |
| | Spinal cord compression | | |
| | subjects affected / exposed | 0 / 29 (0.00%) | |
| | occurrences (all) | 0 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Blood and lymphatic system disorders | Leukopenia | | |
| | subjects affected / exposed | 1 / 29 (3.45%) | |
| | occurrences (all) | 1 | |
| | Anaemia | | |
| | subjects affected / exposed | 0 / 29 (0.00%) | |
| | occurrences (all) | 0 | |
| | Spontaneous haematoma | | |
| | subjects affected / exposed | 0 / 29 (0.00%) | |
| | occurrences (all) | 0 | |
| Ear and labyrinth disorders | Vertigo | | |
| | subjects affected / exposed | 1 / 29 (3.45%) | |
| | occurrences (all) | 1 | |
| | Ear disorder | | |

| | | | |
|--|---------------------|--|--|
| subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 3 / 29 (10.34%) | | |
| occurrences (all) | 3 | | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 2 / 29 (6.90%) | | |
| occurrences (all) | 2 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Toothache | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nausea | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pruritus | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Renal and urinary disorders | | | |
| Pollakiuria | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|-----------------------------|----------------|--|--|
| Back pain | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Cervical spinal stenosis | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Neck pain | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Myalgia | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Spinal pain | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Sacroiliitis | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Wrist deformity | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Infections and infestations | | | |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Herpes zoster | | | |

| | | | |
|------------------------------------|----------------|--|--|
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nasal vestibulitis | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Osteomyelitis | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | | |
| occurrences (all) | 0 | | |
| Sinusitis | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Tooth infection | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 2 / 29 (6.90%) | | |
| occurrences (all) | 2 | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| COVID-19 | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Asymptomatic COVID-19 | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Metabolism and nutrition disorders | | | |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |
| Hypoglycaemia | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | | |
| occurrences (all) | 1 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|---|
| 16 December 2020 | <ul style="list-style-type: none">• Clarifications made to study visit/assessment timings and procedures in relation to screening, pre-dose assessments, home visits, and coagulation parameters• Minor clarifications made in inclusion criterion #7(b) and exclusion criteria #12 and #29• Clarification that participants must not make changes to or take new concomitant medications without Investigator consultation• Discontinuation of study intervention criteria in relation to ALT/AST parameters expanded |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported